Consainsights logo
  • Reports /
  • Biosimilar Testing and Development Services Market

Biosimilar Testing and Development Services Market

Biosimilar Testing and Development Services Market Research Report – Segmented By Clinical Assays (PK ASSAYS, TIERED IMMUNOGENICITY TESTING, NAB ASSAYS), By Comparability Testing (EFFECTOR BINDING BIACORE, C1Q BINDING BY ELISA, KINETIC BINDING ASSAYS BY BIACORE, ADCC AND CDC ASSAYS CELL BASED ASSAYS), By Region (EUROPE, ASIA-PACIFIC, LAMEA) & Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.

Table of contents

Executive Summary

Biosimilar Testing and Development Services Market was valued at US $21.10 billion in 2021 and is projected to grow at 17.21% CAGR over the forecast period to reach US $54.71 billion by 2027. Biosimilar Testing and Development Services Market represented US $5.74 billion opportunity over 2019-2021 and estimated to create US $33.61 billion opportunity in 2027 over 2021.

Biosimilar Testing and Development Services Market Size (2019 - 2027), USD billion

Biosimilar Testing and Development Services from Consainsights analyses the Biosimilar Testing and Development Services Market in the Life Sciences industry over the forecast period to 2027.

Biosimilar Testing and Development Services research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Biosimilar Testing and Development Services segmentation includes Clinical Assays, Comparability Testing, Region and Geography.

Based on the Clinical Assays, the Biosimilar Testing and Development Services analysis covers PK ASSAYS, TIERED IMMUNOGENICITY TESTING, NAB ASSAYS.

In Clinical Assays segment, PK ASSAYS segment has highest cagr growth of 15.16%.

Revenue Share (%), By Clinical Assays (2021)

Based on the Comparability Testing, the Biosimilar Testing and Development Services analysis covers EFFECTOR BINDING BIACORE, C1Q BINDING BY ELISA, KINETIC BINDING ASSAYS BY BIACORE, ADCC AND CDC ASSAYS CELL BASED ASSAYS.

In Comparability Testing segment, EFFECTOR BINDING BIACORE segment has highest cagr growth of 15.16%.

Revenue Share (%), By Comparability Testing (2021)

Based on the Region, the Biosimilar Testing and Development Services analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 15.16%.

Revenue Share (%), By Region (2021)

Based on the region, the Biosimilar Testing and Development Services analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include EUROFINS SCIENTIFIC, SGS SA, CHARLES RIVER LABORATORIES INTERNATIONAL INC., PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC., EXOVA GROUP PLC., SOURCE BIOSCIENCE PLC., INTERTEK GROUP PLC., MEDISTRI SA, PACE ANALYTICAL SERVICES INC., SIGMA-ALDRICH CO. LLC and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Clinical Assays

Introduction

In 2021, PK ASSAYS segment has the highest revenue of US $12.48 billion and is expected to grow at CAGR of 15.16% by 2027 PK ASSAYS segment has highest cagr growth of 15.16%.

Biosimilar Testing and Development Services Market Y-o-Y Growth (USD billion), By Clinical Assays 2019 - 2027
Biosimilar Testing and Development Services Market Size, By Clinical Assays, 2019-2027 (USD billion)

PK ASSAYS

PK ASSAYS segment was valued at US $9.09 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $32.37 billion by 2027. PK ASSAYS segment represented US $3.40 billion opportunity over 2019-2021 and estimated to create US $19.89 billion opportunity in 2027 over 2021.

PK ASSAYS - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

TIERED IMMUNOGENICITY TESTING

TIERED IMMUNOGENICITY TESTING segment was valued at US $3.89 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $13.86 billion by 2027. TIERED IMMUNOGENICITY TESTING segment represented US $1.45 billion opportunity over 2019-2021 and estimated to create US $8.52 billion opportunity in 2027 over 2021.

TIERED IMMUNOGENICITY TESTING - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

NAB ASSAYS

NAB ASSAYS segment was valued at US $2.38 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $8.48 billion by 2027. NAB ASSAYS segment represented US $0.89 billion opportunity over 2019-2021 and estimated to create US $5.21 billion opportunity in 2027 over 2021.

NAB ASSAYS - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

Comparability Testing

Introduction

In 2021, EFFECTOR BINDING BIACORE segment has the highest revenue of US $10.52 billion and is expected to grow at CAGR of 15.16% by 2027 EFFECTOR BINDING BIACORE segment has highest cagr growth of 15.16%.

Biosimilar Testing and Development Services Market Y-o-Y Growth (USD billion), By Comparability Testing 2019 - 2027
Biosimilar Testing and Development Services Market Size, By Comparability Testing, 2019-2027 (USD billion)

EFFECTOR BINDING BIACORE

EFFECTOR BINDING BIACORE segment was valued at US $7.66 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $27.28 billion by 2027. EFFECTOR BINDING BIACORE segment represented US $2.86 billion opportunity over 2019-2021 and estimated to create US $16.76 billion opportunity in 2027 over 2021.

EFFECTOR BINDING BIACORE - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

C1Q BINDING BY ELISA

C1Q BINDING BY ELISA segment was valued at US $3.16 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $11.26 billion by 2027. C1Q BINDING BY ELISA segment represented US $1.18 billion opportunity over 2019-2021 and estimated to create US $6.92 billion opportunity in 2027 over 2021.

C1Q BINDING BY ELISA - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

KINETIC BINDING ASSAYS BY BIACORE

KINETIC BINDING ASSAYS BY BIACORE segment was valued at US $2.66 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $9.49 billion by 2027. KINETIC BINDING ASSAYS BY BIACORE segment represented US $1.00 billion opportunity over 2019-2021 and estimated to create US $5.83 billion opportunity in 2027 over 2021.

KINETIC BINDING ASSAYS BY BIACORE - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

ADCC AND CDC ASSAYS CELL BASED ASSAYS

ADCC AND CDC ASSAYS CELL BASED ASSAYS segment was valued at US $1.88 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $6.68 billion by 2027. ADCC AND CDC ASSAYS CELL BASED ASSAYS segment represented US $0.70 billion opportunity over 2019-2021 and estimated to create US $4.10 billion opportunity in 2027 over 2021.

ADCC AND CDC ASSAYS CELL BASED ASSAYS - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $12.20 billion and is expected to grow at CAGR of 15.16% by 2027 EUROPE segment has highest cagr growth of 15.16%.

Biosimilar Testing and Development Services Market Y-o-Y Growth (USD billion), By Region 2019 - 2027
Biosimilar Testing and Development Services Market Size, By Region, 2019-2027 (USD billion)

EUROPE

EUROPE segment was valued at US $8.88 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $31.64 billion by 2027. EUROPE segment represented US $3.32 billion opportunity over 2019-2021 and estimated to create US $19.44 billion opportunity in 2027 over 2021.

EUROPE - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $3.73 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $13.28 billion by 2027. ASIA-PACIFIC segment represented US $1.39 billion opportunity over 2019-2021 and estimated to create US $8.16 billion opportunity in 2027 over 2021.

ASIA-PACIFIC - Historical, Forecast Market Sizes (USD billion), 2019 - 2027

LAMEA

LAMEA segment was valued at US $2.75 billion in 2019 and is projected to grow at 15.16% CAGR over the forecast period to reach US $9.79 billion by 2027. LAMEA segment represented US $1.03 billion opportunity over 2019-2021 and estimated to create US $6.02 billion opportunity in 2027 over 2021.

LAMEA - Historical, Forecast Market Sizes (USD billion), 2019 - 2027